Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.27
HRT's Cash to Debt is ranked lower than
55% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. HRT: 0.27 )
HRT' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: 0.27

Equity to Asset 0.39
HRT's Equity to Asset is ranked lower than
54% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. HRT: 0.39 )
HRT' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.96
Current: 0.39

0.39
0.96
F-Score: 6
Z-Score: 1.91
M-Score: -3.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -4.48
HRT's Operating margin (%) is ranked higher than
56% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. HRT: -4.48 )
HRT' s 10-Year Operating margin (%) Range
Min: -15.6   Max: 21.71
Current: -4.48

-15.6
21.71
Net-margin (%) -16.58
HRT's Net-margin (%) is ranked higher than
52% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. HRT: -16.58 )
HRT' s 10-Year Net-margin (%) Range
Min: -29.73   Max: 16.4
Current: -16.58

-29.73
16.4
ROE (%) -55.75
HRT's ROE (%) is ranked lower than
55% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. HRT: -55.75 )
HRT' s 10-Year ROE (%) Range
Min: -63.3   Max: 15.35
Current: -55.75

-63.3
15.35
ROA (%) -21.64
HRT's ROA (%) is ranked higher than
51% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. HRT: -21.64 )
HRT' s 10-Year ROA (%) Range
Min: -36.19   Max: 13.85
Current: -21.64

-36.19
13.85
ROC (Joel Greenblatt) (%) -9.44
HRT's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. HRT: -9.44 )
HRT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -38.73   Max: 36.28
Current: -9.44

-38.73
36.28
Revenue Growth (%) -2.10
HRT's Revenue Growth (%) is ranked higher than
59% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. HRT: -2.10 )
HRT' s 10-Year Revenue Growth (%) Range
Min: -25.3   Max: 34.6
Current: -2.1

-25.3
34.6
EBITDA Growth (%) -35.30
HRT's EBITDA Growth (%) is ranked higher than
55% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. HRT: -35.30 )
HRT' s 10-Year EBITDA Growth (%) Range
Min: -35.3   Max: 39.9
Current: -35.3

-35.3
39.9
» HRT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HRT Guru Trades in Q1 2013

Jim Simons 56,300 sh (-0.18%)
» More
Q2 2013

HRT Guru Trades in Q2 2013

Jim Simons 56,100 sh (-0.36%)
» More
Q3 2013

HRT Guru Trades in Q3 2013

Jim Simons 56,100 sh (unchged)
» More
Q4 2013

HRT Guru Trades in Q4 2013

Jim Simons 56,900 sh (+1.43%)
» More
» Details

Insider Trades

Latest Guru Trades with HRT



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.10
HRT's P/B is ranked higher than
72% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. HRT: 2.10 )
HRT' s 10-Year P/B Range
Min: 0.26   Max: 12.47
Current: 2.1

0.26
12.47
P/S 0.60
HRT's P/S is ranked higher than
92% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. HRT: 0.60 )
HRT' s 10-Year P/S Range
Min: 0.2   Max: 14.62
Current: 0.6

0.2
14.62
EV-to-EBIT 11.60
HRT's EV-to-EBIT is ranked higher than
87% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. HRT: 11.60 )
HRT' s 10-Year EV-to-EBIT Range
Min: 4   Max: 69.2
Current: 11.6

4
69.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.20
HRT's Price/Tangible Book is ranked higher than
79% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. HRT: 2.20 )
HRT' s 10-Year Price/Tangible Book Range
Min: 0.38   Max: 10.73
Current: 2.2

0.38
10.73
Price/DCF (Projected) 100.20
HRT's Price/DCF (Projected) is ranked lower than
83% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. HRT: 100.20 )
HRT' s 10-Year Price/DCF (Projected) Range
Min: 0.26   Max: 63.4
Current: 100.2

0.26
63.4
Price/Median PS Value 0.90
HRT's Price/Median PS Value is ranked higher than
79% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. HRT: 0.90 )
HRT' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 14.76
Current: 0.9

0.33
14.76
Forward Rate of Return (Yacktman) -0.73
HRT's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. HRT: -0.73 )
HRT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -12.8   Max: 41.9
Current: -0.73

-12.8
41.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Arrhythmia Research Technology was incorporated under the laws of the State of Louisiana in 1981 and reincorporated under the laws of the State of Delaware in 1987. It completed an initial public offering in 1988. The Company through its wholly-owned subsidiary is a manufacturer specializing in plastic molding, precision metal and plastics machining and precious metal coating. It is also engaged in the development and licensing of signal averaged electrocardiography (SAECG) software, through its Predictor brand. The Company's technologies used in analyzing high resolution heart signals. Its Predictor software is used in research and clinical environments to diagnose the risk of certain heart arrhythmias. The Company invests in research and development, product support and sales efforts. The Company sells its services to its customers to provide product life cycle support to their product manufacturing needs. It provides complex value added US based manufacturing capabilities in injection molding, machining and plating/coating, mold making, maintenance and repair. The Company's operations are subject to government regulations which establish compliance standards and result in costs to comply in order to participate in certain markets.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide